This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
The disclosure included in this article states:
“Dr. Leppik has received honoraria from Abbott Laboratories, Pfizer, and UCB Pharma. Dr. Cloyd has received honoraria from Elan Pharmaceuticals and GlaxoSmithKline, honoraria in excess of $10,000 from Abbott Laboratories and Ovation Pharmaceuticals, and a grant in excess of $10,000 from Novartis.”
But on another website (http://www.princetoncme.com/public/2004-79-4/) I found the following disclosure:
“Ilo E. Leppik, MD: Honoraria/Consultant/Speaker/Grant–Abbott Laboratories, AstraZeneca, Athena, Bristol-Myers Squibb, Carter-Wallace, Cephalon, Ciba-Geigy, Cognetix, Cyberonics, Dainippon, Elan Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Hoechst Marion Roussel, MedPointe, Medtronic, Merck Sharp & Dohme, Novartis, Ortho-McNeil, Parke-Davis, Pfizer, Shire, Synthe Labo, UCB Pharma, Inc., Upshire-Smith, Wyeth Ayerst, Xcel Pharmaceuticals.”
Since my understanding is that Parke-Davis manufacture brand name phenytoin, I would suggest that these differences deserve explanation. And perhaps a follow-up study of the bioequivalence of generic and brand name phenytoin by a different, independent group is in order.
To the Editor:
Burkhardt et al.1 identified a case series of “… adult patients whose seizures increased enough to require intervention.” The authors determined that of the 11 cases, 10 had been switched from brand to generic phenytoin and concluded that use of the generic product resulted in lower phenytoin blood levels than the brand product in eight of these patients. We can not assess the strength of the finding from the information provided in the publication. Additional information provided by the authors has been insufficient. The case definition and methods used for case identification are unclear.
We expected that the authors would have used a well-defined denominator of patients and a control group of patients who were candidates to switch from brand to generic phenytoin and matched by disease severity. Both groups would be followed to determine the rate of lowered phenytoin blood levels and worsening of underlying seizure control. …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Lower phenytoin serum levels in persons switched from brand to generic phenytoin
Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding
Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes
2012 Emerging Science Abstracts